Radiation and Concomitant Chemotherapy for Patients with Glioblastoma Multiforme

Overview

Journal Chin J Cancer

Publisher Biomed Central

Specialty Oncology

Date 2013 Dec 12

PMID 24325790

Citations 15

Authors

Salvador Villa

Carme Balana

Silvia Comas

Affiliations

Soon will be listed here.

Abstract

Postoperative external beam radiotherapy was considered the standard adjuvant treatment for patients with glioblastoma multiforme until the advent of using the drug temozolomide (TMZ) in addition to radiotherapy. High-dose volume should be focal, minimizing whole brain irradiation. Modern imaging, using several magnetic resonance sequences, has improved the planning target volume definition. The total dose delivered should be in the range of 60 Gy in fraction sizes of 1.8-2.0 Gy. Currently, TMZ concomitant and adjuvant to radiotherapy has become the standard of care for glioblastoma multiforme patients. Radiotherapy dose-intensification and radiosensitizer approaches have not improved the outcome. In spite of the lack of high quality evidence, stereotactic radiotherapy can be considered for a selected group of patients. For elderly patients, data suggest that the same survival benefit can be achieved with similar morbidity using a shorter course of radiotherapy (hypofractionation). Elderly patients with tumors that exhibit methylation of the O-6-methylguanine-DNA methyltransferase promoter can benefit from TMZ alone.

Citing Articles

Survival prediction of glioblastoma patients using modern deep learning and machine learning techniques.

Babaei Rikan S, Sorayaie Azar A, Naemi A, Bagherzadeh Mohasefi J, Pirnejad H, Wiil U Sci Rep. 2024; 14(1):2371.

PMID: 38287149 PMC: 10824760. DOI: 10.1038/s41598-024-53006-2.

Long-Term Cultured Human Glioblastoma Multiforme Cells Demonstrate Increased Radiosensitivity and Senescence-Associated Secretory Phenotype in Response to Irradiation.

Alhaddad L, Nofal Z, Pustovalova M, Osipov A, Leonov S Int J Mol Sci. 2023; 24(3).

PMID: 36768320 PMC: 9916727. DOI: 10.3390/ijms24032002.

Exploring the Physical and Biological Aspects of BNCT with a Carboranylmethylbenzo[]acridone Compound in U87 Glioblastoma Cells.

Belchior A, Fernandes A, Lamotte M, Silva A, Seixas R, Silva A Int J Mol Sci. 2022; 23(23).

PMID: 36499256 PMC: 9737597. DOI: 10.3390/ijms232314929.

Central Nervous System Plasticity Influences Language and Cognitive Recovery in Adult Glioma.

Krishna S, Kakaizada S, Almeida N, Brang D, Hervey-Jumper S Neurosurgery. 2021; 89(4):539-548.

PMID: 33476391 PMC: 8440067. DOI: 10.1093/neuros/nyaa456.

Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study.

Rosenthal M, Clement P, Campone M, Gil-Gil M, DeGroot J, Chinot O ESMO Open. 2020; 5(4).

PMID: 32665311 PMC: 7359195. DOI: 10.1136/esmoopen-2020-000672.

References

Bleehen N, Stenning S . A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer. 1991; 64(4):769-74. PMC: 1977696. DOI: 10.1038/bjc.1991.396. View

Urtasun R, Band P, Chapman J, Feldstein M, Mielke B, Fryer C . Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med. 1976; 294(25):1364-7. DOI: 10.1056/NEJM197606172942503. View

Brandes A, Tosoni A, Franceschi E, Sotti G, Frezza G, Amista P . Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol. 2009; 27(8):1275-9. DOI: 10.1200/JCO.2008.19.4969. View

Coughlin C, Scott C, Langer C, Coia L, Curran W, Rubin P . Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed.... Int J Radiat Oncol Biol Phys. 2000; 48(5):1351-8. DOI: 10.1016/s0360-3016(00)01412-7. View

Prokic V, Wiedenmann N, Fels F, Schmucker M, Nieder C, Grosu A . Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: a planning study on treatment concepts. Int J Radiat Oncol Biol Phys. 2012; 85(1):264-70. DOI: 10.1016/j.ijrobp.2012.02.036. View

Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G . Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007; 356(15):1527-35. DOI: 10.1056/NEJMoa065901. View

Stewart L . Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002; 359(9311):1011-8. DOI: 10.1016/s0140-6736(02)08091-1. View

Horiot J, Van Den Bogaert W, Ang K, van der Schueren E, Bartelink H, Gonzalez D . European Organization for Research on Treatment of Cancer trials using radiotherapy with multiple fractions per day. A 1978-1987 survey. Front Radiat Ther Oncol. 1988; 22:149-61. DOI: 10.1159/000415105. View

Nelson D, Curran Jr W, Scott C, Nelson J, Weinstein A, Ahmad K . Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys. 1993; 25(2):193-207. DOI: 10.1016/0360-3016(93)90340-2. View

10.

Brada M, Sharpe G, Rajan B, Britton J, Wilkins P, Guerrero D . Modifying radical radiotherapy in high grade gliomas; shortening the treatment time through acceleration. Int J Radiat Oncol Biol Phys. 1999; 43(2):287-92. DOI: 10.1016/s0360-3016(98)00390-3. View

11.

Baumert B, Brada M, Bernier J, Kortmann R, Dehing-Oberije C, Collette L . EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm. Radiother Oncol. 2008; 88(2):163-72. DOI: 10.1016/j.radonc.2008.03.025. View

12.

Floyd N, Woo S, Teh B, Prado C, Mai W, Trask T . Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2004; 58(3):721-6. DOI: 10.1016/S0360-3016(03)01623-7. View

13.

Taal W, Brandsma D, de Bruin H, Bromberg J, Swaak-Kragten A, Sillevis Smitt P . Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008; 113(2):405-10. DOI: 10.1002/cncr.23562. View

14.

Dhermain F, Hau P, Lanfermann H, Jacobs A, van den Bent M . Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010; 9(9):906-20. DOI: 10.1016/S1474-4422(10)70181-2. View

15.

Wallner K, Galicich J, Krol G, Arbit E, Malkin M . Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 1989; 16(6):1405-9. DOI: 10.1016/0360-3016(89)90941-3. View

16.

Malmstrom A, Gronberg B, Marosi C, Stupp R, Frappaz D, Schultz H . Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012; 13(9):916-26. DOI: 10.1016/S1470-2045(12)70265-6. View

17.

PRADOS M, Wara W, Sneed P, McDermott M, Chang S, Rabbitt J . Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001; 49(1):71-7. DOI: 10.1016/s0360-3016(00)01458-9. View

18.

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

19.

Binello E, Green S, Germano I . Radiosurgery for high-grade glioma. Surg Neurol Int. 2012; 3(Suppl 2):S118-26. PMC: 3400492. DOI: 10.4103/2152-7806.95423. View

20.

Graus F, Bruna J, Pardo J, Escudero D, Vilas D, Barcelo I . Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain. Neuro Oncol. 2013; 15(6):797-805. PMC: 3661097. DOI: 10.1093/neuonc/not013. View